2026-06-12T12:07:53+00:00 2025-09-30 440160260 Forvis Mazars LLP 1201 Walnut Street Suite 1700 Kansas City MO 641062246 990 2024-10-01 440545878 MRIGlobal MRIG 8167537600 425 DR MARTIN LUTHER KING JR BLVD KANSAS CITY MO 64110 IAN M COLRAIN PRESIDENT & CEO 8167537600 2026-06-12 true Michael Engle P00482834 8162216300 2026-08-17 2024 2025-03-06 01:10:19Z IAN M COLRAIN 425 DR MARTIN LUTHER KING JR BLVD KANSAS CITY MO 64110 116605334 false X WWW.MRIGLOBAL.ORG X 1943 MO Advance scientific and engineering research to support our government and commercial customers. 15 14 497 0 5731617 372747 80032509 87513057 36342036 26075073 1558270 2155629 20137 105990 117952952 115849749 25000 25000 0 57718638 55860018 0 0 57554420 65913444 115298058 121798462 2654894 -5948713 147828702 140070332 37025718 29036552 110802984 111033780 To improve the lives of people through innovative scientific and engineering research. false false 36380350 25000 10893593 Integrated Health Surveillance and Diagnostics - MRIGlobal performs research to counter threats to human health. In our world-class laboratories, our team supports all phases of immuno and molecular assays in our CAP/CLIA certified labs. Our capabilities range from the development of cutting-edge molecular and immunological assays focused on emerging highly infectious diseases, researching vaccines and therapeutics, and the advancement of novel, highly sensitive diagnostic assays, ushering them all through regulatory clearance. 42062523 0 1205221 Integrated Defense Solutions - MRIGlobal guards human health and safety by defending against chemical, biological, and explosive threats. With decades of chemical warfare agent detection, evaluation, and assessment, our unique expertise and history combines scientific and engineering experts with state-of-the-art laboratory facilities to advance programs across the United States government and private sectors. This includes the design, building, testing, and evaluation of advanced products and technologies such as miniature devices capable of detecting toxic materials and chemical agents, field-deployable laboratories, and medical response systems that improve national defense and global health. 16993626 0 8244642 Integrated Pharmaceutical Solutions - MRIGlobal bridges the gap between drug discovery and commercialization. We provide the necessary services including development, manufacturing, testing, and clinical trial material management support for drug substances, drug products, intermediates, and impurities, including reference standard materials. Our team works in the appropriate regulatory framework, such as GLP, GMP, and in accordance with ICH guidelines to ensure strict compliance to quality and regulatory requirements. This work helps support informed public health decisions, and guiding investigational new drugs through development, clinical trials, and regulatory approvals. 95436499 true true false true false false false false false false true false false true true true false true false true true false false false false false false true false true true false false false false false false false false false false false false false false true false false false false false true 116 0 true 497 true true true false false false false false false false false false false false X 15 14 true false true false false false false true true false false false true true true true true true true true false false X STEPHANIE DEFINO 8167537600 425 DR MARTIN LUTHER KING JR BLVD KANSAS CITY MO 64110 Ian M Colrain PhD President and CEO 40.0 0.0 X X 943691 0 85333 Alexander G Garza MD MPH Director 1.0 0.0 X 40000 0 0 Amy Nachtigal Director 1.0 0.0 X 47500 0 0 Dan E Arvizu PhD Director 1.0 0.0 X 40000 0 0 David E Hall Director 1.0 0.0 X 47500 0 0 Douglas A Girod MD Director 1.0 0.0 X 40000 0 0 Heather Leith Director 1.0 0.0 X 40000 0 0 Josh Carpenter DPhil Director 1.0 0.0 X 0 0 0 Julia M Wilson Director 1.0 0.0 X 40000 0 0 Laura Wright Director 1.0 0.0 X 40000 0 0 Neal Sharma Director 1.0 0.0 X 40000 0 0 Pamela R Berneking Director 1.0 0.0 X 55000 0 0 Scott M Smith PE Director 1.0 0.0 X 47500 0 0 Steffanie B Easter Director 1.0 0.0 X 40000 0 0 Wendy M Masiello Director 1.0 0.0 X 40000 0 0 William A Jeffrey PhD Director 1.0 0.0 X 47500 0 0 Amy M Bog PhD Chief Innovation Officer 40.0 0.0 X 400380 0 33509 Jessica J Zolynas Chief Legal Officer & Corp Secretary 40.0 0.0 X 364629 0 35768 Luke J McGlynn Chief People Officer 40.0 0.0 X 370224 0 61792 Martin J Nevshemal CFO and Treasurer - Outgoing 40.0 0.0 X 509061 0 72181 Stephanie DeFino CFO and Treasurer 40.0 0.0 X 0 0 0 Jason E Gordon Senior Director 40.0 0.0 X 209916 0 38529 Jonathan M White Senior Director 40.0 0.0 X 220131 0 48344 Kristine K Werking Senior Director 40.0 0.0 X 264020 0 49318 Dominie Garcia PhD VP-Commercial Business Development 40.0 0.0 X 353318 0 35938 Jerem G Swenddal VP-Business Ops & Strategy 40.0 0.0 X 275198 0 22590 Joseph A Bogan Jr PhD Chief Research Fellow 40.0 0.0 X 343045 0 28029 Michelle Rodrigues VP-Government Business Development 40.0 0.0 X 300450 0 31829 Richard A Winegar Distinguished Research Fellow 40.0 0.0 X 286722 0 31815 Carol F Blevins Assistant Director 40.0 0.0 X 194109 0 36128 Christopher W Hollars Principal Advisor 40.0 0.0 X 234275 0 40044 5874169 0 651147 144 true true false Biomeme 401 N Broad Street Philadelphia PA 19108 Research & Development 5268450 Lifelens Technologies Inc 1 Ivybrook Boulevard Ivyland PA 18974 Research & Development 2294126 HHI Corporation 49 North Main Farmington UT 84025 Research & Development 1617690 Draper Laboratory 555 Technology Square Cambridge MA 02139 Research & Development 1539005 Kiple Acquisition Science Technology Logistics & Engineering Inc 1704 Connor Place Forest Hill MD 21050 Research & Development 1527758 27 87513057 87513057 Research Contracts 541700 26075073 20343456 5731617 0 0 0 0 0 26075073 2092068 2092068 0 0 748809 70337 651715 103870 97094 -33533 63561 63561 Miscellaneous 900099 105990 105990 0 0 0 0 105990 115849749 20343456 5731617 2261619 25000 25000 4728742 866558 3862184 38440498 27689443 10751055 4114069 2905625 1208444 5530809 3614423 1916386 3045900 2096267 949633 0 0 0 666887 240217 426670 256286 256286 5000 5000 21879 21879 7996830 4165329 3831501 0 2160772 1890126 270646 1144775 834930 309845 5858841 5044352 814489 1218659 790673 427986 264553 103948 160605 187149 157526 29623 5250084 4819240 430844 437950 65419 372531 Subcontracts 28398835 28398835 Non-capital equipment 5208344 5178110 30234 Lab supplies 4935844 4935844 Bad Debt Expense 714728 714728 1186028 894906 291122 0 121798462 95436499 26361963 0 50570189 52501250 130451 0 12088081 9083597 0 0 0 0 1015218 1099010 1600986 1673222 116139093 73037901 46198090 43101192 10703798 11697645 0 2948972 2824224 22572917 18090192 147828702 140070332 11379693 11012295 8245265 6978347 0 0 299742 177791 1145172 0 15955846 10868119 37025718 29036552 X 109182652 110402386 1620332 631394 110802984 111033780 147828702 140070332 X -5948713 644521 0 0 0 5534988 X false true true true true X 64550069 78663392 74814815 80032509 87513057 385573842 44011112 40612662 33331903 29832465 20343456 168131598 0 0 0 108561181 119276054 108146718 109864974 107856513 553705440 2331451 1695000 120000 0 0 4146451 19471406 12874761 9367787 7846379 6925067 56485400 21802857 14569761 9487787 7846379 6925067 60631851 493073589 553731 1192601 1435390 2376490 2092068 7650280 798207 1141232 382635 590409 372747 3285230 1351938 2333833 1818025 2966899 2464815 10935510 0 0 0 0 0 6935 11743 9255 20137 105990 154060 109920054 121621630 109973998 112852010 110427318 564795010 0.87301 0.84959 0.02 0.02 X Schedule A, Part III, Line 12 Other Income DESCRIPTION - MISCELLANEOUS INCOME, COLUMN A - 6935.0, COLUMN B - 11743.0, COLUMN C - 9255.0, COLUMN D - 20137.0, COLUMN E - 105990.0, COLUMN F - 154060.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false false false false false false true 5000 false false 5000 false Schedule C, Part II-B, Line 1 DETAILED DESCRIPTION OF THE LOBBYING ACTIVITY LOBBYING ACTIVITIES RELATED TO MISSOURI PROPERTY TAX REFORM BILL AND NOT FOR PROFIT ORGANIZATION EXEMPTION. 2349104 2349104 72021445 44442873 27578572 0 0 0 40446978 28595028 11851950 1321566 0 1321566 43101192 Contracts in Progress 11249625 Right-of-Use Asset 3510299 457(b) Assets 3086347 Other 243921 18090192 Federal Income Taxes Pension Benefit Liability Operating Lease Liability 3468197 457(b) Liability 3086347 Long-Term Liabilities 2692423 Excess Billings 1621152 10868119 X 0 0 0 0 0 0 0 0 0 0 0 0 Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote Uncertain tax positions are recognized if it is more likely than not, based on the technical merits, that the tax position will be realized or sustained upon examination. Recognized income tax positions are initially and subsequently measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon settlement with a taxing authority that has full knowledge of all relevant information. The determination of whether or not a tax position has met the more-likely-than-not recognition threshold considers the facts, circumstances and information available at the reporting date and is subject to management's judgment. No amounts have been recorded at September 30, 2025, with respect to uncertain tax positions. Europe (Including Iceland and Greenland) 0 15 Program Services R & D 2258651 East Asia and the Pacific 0 2 Program Services R & D 315254 0 17 0 0 0 17 2573905 0 2573905 false false false false false false Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual true Union Station Kansas City Inc 30 W Pershing Rd Kansas City MO 64108 431890025 501(c)(3) 25000 Foster scientific education 1 0 Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds MRIGlobal monitors its grants through active participation and/or as part of the institutional governance of the receiving organization to ensure the grants are used for proper purposes. X true true X X X X false true false false false false false true false Ian M Colrain PhD President and CEO 635145 0 301022 0 7524 0 75189 0 10144 0 1029024 0 0 0 Martin J Nevshemal CFO and Treasurer - Outgoing 372394 0 97127 0 39540 0 38542 0 33639 0 581242 0 35544 0 Amy M Bog PhD Chief Innovation Officer 300943 0 82884 0 16553 0 27600 0 5909 0 433889 0 0 0 Luke J McGlynn Chief People Officer 291434 0 73887 0 4903 0 30077 0 31715 0 432016 0 0 0 Jessica J Zolynas Chief Legal Officer & Corp Secretary 341677 0 21818 0 1134 0 24659 0 11109 0 400397 0 0 0 Christopher W Hollars Principal Advisor 206579 0 26666 0 1030 0 19281 0 20763 0 274319 0 0 0 Carol F Blevins Assistant Director 173158 0 18008 0 2943 0 15808 0 20320 0 230237 0 0 0 Kristine K Werking Senior Director 234737 0 28080 0 1203 0 21754 0 27564 0 313338 0 0 0 Jonathan M White Senior Director 200363 0 18633 0 1135 0 18441 0 29903 0 268475 0 0 0 Jason E Gordon Senior Director 193236 0 16046 0 634 0 17438 0 21091 0 248445 0 0 0 Richard A Winegar Distinguished Research Fellow 258402 0 24590 0 3730 0 22820 0 8995 0 318537 0 0 0 Dominie Garcia PhD VP-Commercial Business Development 284658 0 66969 0 1691 0 27600 0 8338 0 389256 0 0 0 Jerem G Swenddal VP-Business Ops & Strategy 242894 0 31525 0 779 0 21954 0 636 0 297788 0 0 0 Joseph A Bogan Jr PhD Chief Research Fellow 273581 0 66905 0 2559 0 27239 0 790 0 371074 0 0 0 Michelle Rodrigues VP-Government Business Development 298920 0 0 0 1530 0 23000 0 8829 0 332279 0 0 0 Schedule J, Part I, Line 1a First-class or charter travel Ian M. Colrain occasionally flew first class on certain legs of business trips. This was not treated as taxable compensation to him. Schedule J, Part I, Line 4b Supplemental nonqualified retirement plan THE FOLLOWING AMOUNTS WERE ACCRUED AND/OR PAID TO A 457(F) PLAN: Ian M. Colrain - Accrued $47,589; Paid $0. Martin J. Nevshemal - Accrued $10,942; Paid $35,544 Luke J. McGlynn - Accrued $2,477; Paid $0. Jessica J. Zolynas - Accrued $1,659; Paid $0. Schedule J, Part I, Line 7 Non-fixed payments Incentive compensation awards are payable if the MRIGlobal Board-approved annual operating plan objectives are achieved. Total annual incentive compensation is awarded to individual participants and is based on organizational performance and individual performance. The incentive compensation participants are categorized in two plans with assigned ranges of target incentive percentages. Participants' target incentive is a percentage of their base pay. Participants are eligible to receive 100% of their target incentive compensation if the annual operating plan objectives are achieved. If the objectives are not achieved but research operations realizes the objectives were partially met, participants will receive a pro rata portion of their target incentive. If objectives are exceeded, participants are eligible to receive incentive payments ranging from 1 to 1.5 times their target incentive. A Missouri Development Finance Board 431387649 000000000 2020-09-01 13020000 See Part VI false false false A 6025000 13020000 13020000 2010 true false true true A false false false false true false 0.0 0.0 0.0 false false 0 false true A false false true false true false 0 false false false 0 false false true A true Schedule K, Part I, Column (f) Line A THE 2015 BONDS (ORIGINALLY ISSUED ON 8/26/2015) WERE ISSUED TO REFUND 2007 BONDS (ORIGINALLY ISSUED ON 3/28/2007) AND WERE DEEMED REISSUED AND CURRENTLY REFUNDED (9/1/2020) IN CONNECTION WITH CERTAIN AMENDMENTS TO THE 2015 BOND DOCUMENTS. Schedule K, Part II, Line 1 Column A THIS REPRESENTS THE CUMULATIVE PRINCIPAL AMOUNT OF 2015 BONDS PAID AFTER THE REISSUANCE DATE. Schedule K, Part II, Line 3 Column A AMOUNT REPRESENTS THE TOTAL AMOUNT OF THE 2015 BONDS THAT WERE DEEMED RETIRED, REISSUED AND CURRENTLY REFUNDED AS OF THE REISSUANCE DATE. Schedule K, Part II, Line 11 Column A AMOUNT REPRESENTS THE TOTAL AMOUNT OF THE 2015 BONDS THAT WERE DEEMED RETIRED, REISSUED AND CURRENTLY REFUNDED AS OF THE REISSUANCE DATE. Schedule K, Part III, Line 3c Column A RESEARCH AGREEMENTS IN FORCE DURING THE REPORTING PERIOD RELATING TO WORK PERFORMED IN THE SPACE ALLOCABLE TO THE PORTION OF THE FACILITIES FINANCED BY THE 2015 BONDS ARE NOT TREATED AS RESULTING IN NON-QUALIFIED USE PER REGULATIONS SECTION 1.141-3(B)(6) AND REVENUE PROCEDURE 2007-47. Schedule K, Part III, Line 3d Column A THE INSTITUTION USES THE STANDARDS SET FORTH IN THE TAX COMPLIANCE AGREEMENT EXECUTED AT THE TIME THE 2015 BONDS WERE ISSUED AS WELL AS ITS TAX-EXEMPT FINANCING COMPLIANCE PROCEDURE TO DETERMINE WHETHER ANY RESEARCH AGREEMENT HAS THE POTENTIAL TO RESULT IN NON-QUALIFIED USE OF THE 2015 BOND FINANCED FACILITIES. AS A RESULT, MRIGLOBAL HAS NOT HAD A NEED TO CONSULT WITH BOND COUNSEL TO REVIEW ITS RESEARCH AGREEMENTS. Form 990, Part VI, Line 1a Delegate broad authority to a committee The governing body has delegated authority to act on its behalf to an Executive Committee. The Executive Committee may exercise any and all powers of the Board of Directors subject to the paramount power of the Board. The Executive Committee may convene between Board meetings to make decisions that cannot be delayed until the next Board meeting. The Executive Committee members are all voting directors. Specifically, the Executive Committee is comprised of the Chair of the Board, Vice Chair of the Board, Chair of the Finance and Audit Committee, Chair of the Nominating and Governance Committee, and Chair of the Compensation and HR Committee. Form 990, Part VI, Line 2 Family/business relationships amongst interested persons William A. Jeffrey, Ph.D. and Laura Wright - Business relationship Form 990, Part VI, Line 4 Significant changes to organizational documents The Bylaws were updated as follows: added narrative regarding resignation and leave of absence for directors, removed language regarding trustee as committee member, added the president as an ex officio voting member of all Board committees, corrected title of Chief People Officer, and removed references to CIO position. Form 990, Part VI, Line 11b Review of form 990 by governing body REVIEW OF 990 PRIOR TO FILING THE 990 IS REVIEWED BY MRIGLOBAL STAFF, INCLUDING THE CFO, CONTROLLER, AND CHIEF LEGAL OFFICER. A FINAL DRAFT VERSION IS ALSO REVIEWED BY MRIGLOBAL'S FINANCE AND AUDIT COMMITTEE. EACH MEMBER OF THE BOARD OF DIRECTORS RECEIVES A FINAL DRAFT VERSION OF THE 990 PRIOR TO THE APPLICABLE BOARD OF DIRECTORS' MEETING. ANY UPDATES RESULTING FROM THE REVIEW BY THE FINANCE AND AUDIT COMMITTEE ARE PRESENTED TO THE BOARD OF DIRECTORS AT THIS MEETING. Form 990, Part VI, Line 12c Conflict of interest policy Monitoring and Enforcement of Board Independence The officers, directors, and key employees of MRIGlobal are required to complete a disclosure statement on an annual basis. The disclosures set forth on the statements are presented to the Finance and Audit Committee of the MRIGlobal Board of Directors by the MRIGlobal Compliance Officer. The Finance and Audit Committee discusses the disclosure statements to determine if any potential conflict-of-interest situations exist with respect to the officers, directors, and key employees of MRIGlobal. At the following MRIGlobal Board meeting, an executive summary of the disclosure statements is presented to the Directors and the Finance and Audit Committee reports the outcome of its discussion to the Directors. The Directors are presented the opportunity to discuss the Finance and Audit Committee's findings or any other potential conflict-of-interest issues presented in the executive summary. Ultimately, the Board of Directors will determine whether a conflict of interest exists with respect to any officer, director, or key employee of MRIGlobal. The Finance and Audit Committee's findings and the Directors' discussion of potential conflict-of-interest situations are recorded in the minutes of the Board meeting, including determination of whether a conflict of interest exists, the names of the individuals involved, the nature of the potential conflict, the action taken, and the basis on which the Board reached its decision. MRIGlobal has certain procedures with respect to addressing a conflict-of-interest transaction. Any action to be taken by MRIGlobal involving or pertaining to an individual, entity or circumstance with respect to which an officer, director, or key employee (each, a covered person) has a conflicting interest will be discussed and voted on by the Board of Directors. The covered person will leave the meeting during the discussion of, and the vote on, the transaction or arrangement that may result in a conflict of interest. In considering any such action to be taken, the Board will undertake appropriate due diligence and inform itself of all material information reasonably available to it and explore all reasonable alternatives to the proposed action that would not involve the conflict of interest. The standard for the determination of whether to undertake the proposed action is whether such action is, based on a reasonable good-faith belief, (I) in MRIGlobal's best interest, (II) for its own benefit, and (III) fair and reasonable to MRIGlobal. The Board will document whether or not the conflict-of-interest transaction was approved, the names of the persons present for the discussion and vote, the content of the discussion, whether alternatives were discussed that did not involve a conflict of interest, the basis for the determination that the transaction was (I) in MRIGlobal's best interest, (II) for its own benefit, and (III) fair and reasonable to MRIGlobal, and the record of the vote taken with respect to who voted to approve the transaction. If the Board has reasonable cause to believe that a covered person has failed to disclose a conflict-of-interest situation, it will afford the covered person an opportunity to explain the alleged failure to disclose. If, after hearing the response of the covered person and making such further investigation as may be warranted under the circumstances, the Board determines that the covered person has in fact failed to disclose a conflict-of-interest situation, it will take appropriate corrective actions. The MRIGlobal conflict-of-interest policy requires that the officers, directors, and employees of MRIGlobal disclose any potential conflict-of-interest situation to the appropriate party, including an employee's supervisor, a representative of Human Resources, the Compliance Officer, the Board of Directors, or the MRIGlobal Ethics Hotline, upon awareness that a conflict of interest may exist. Potential conflict-of-interest situations associated with employees (other than officers, directors, and key employees) are handled by the MRIGlobal Compliance Officer, in collaboration with the employee's supervisor and MRIGlobal Executive Management, as appropriate. All MRIGlobal employees are required on an annual basis to complete a compliance questionnaire, which affords them the opportunity to disclose any potential conflict-of-interest situations that have not already been reported or to certify that they are not aware of any potential conflict-of-interest situations. Failure to disclose a potential conflict of interest situation may result in corrective action to the employee. Form 990, Part VI, Line 15a Process to establish compensation of top management official MRIGlobal's Compensation and HR Committee (Committee) of the Board of Directors is responsible for reviewing and approving executive compensation in all areas. On an annual basis, the Committee reviews and approves compensation for executive officers of the organization. The Committee reviews and approves the CEO's performance evaluations and compensation recommendations for the executives. The Committee is informed of summary data on the organization's employee population (e.g. total personnel costs, employee diversity, turnover, etc.). The Committee utilizes compensation survey data, provided by an outside party, to benchmark compensation against similarly situated companies. The Committee's minutes document the decisions and basis used for MRIGlobal's executive compensation. Form 990, Part VI, Line 15b Process to establish compensation of other employees See response for Part VI, Line 15a Form 990, Part VI, Line 19 Required documents available to the public GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, FINANCIAL STATEMENTS - MRIGLOBAL'S GOVERNING DOCUMENTS AND FINANCIAL STATEMENTS ARE MADE AVAILABLE TO THE PUBLIC UPON REQUEST. MRIGLOBAL'S CONFLICT-OF-INTEREST POLICY IS NOT MADE AVAILABLE TO THE PUBLIC. Form 990, Part XI, Line 9 Other changes in net assets or fund balances EQUITY IN EARNINGS OF ALLIANCE LLC - 5674147; PENSION ADJUSTMENT - -15157; Loss on uncollectible pledges - -18451; CHANGE IN FAIR VALUE OF INTEREST SWAP - -105551; Total - 5534988; MRIGlobal - Kansas LLC 2005 Research Park Circle Manhattan KS 66502 440545878 Research & Development KS 0 0 MRIGlobal